Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

BUY
$43.66 - $61.0 $2.22 Million - $3.1 Million
50,890 Added 82.26%
112,756 $6.07 Million
Q2 2022

Aug 11, 2022

BUY
$28.82 - $77.35 $996,941 - $2.68 Million
34,592 Added 126.83%
61,866 $2.5 Million
Q1 2022

May 12, 2022

SELL
$48.25 - $100.49 $3.04 Million - $6.34 Million
-63,106 Reduced 69.82%
27,274 $1.81 Million
Q4 2021

Feb 11, 2022

BUY
$88.71 - $120.43 $5.75 Million - $7.81 Million
64,869 Added 254.28%
90,380 $9.04 Million
Q3 2021

Nov 12, 2021

SELL
$98.77 - $132.17 $889,917 - $1.19 Million
-9,010 Reduced 26.1%
25,511 $3.19 Million
Q2 2021

Aug 10, 2021

SELL
$109.77 - $165.68 $5.6 Million - $8.45 Million
-51,024 Reduced 59.65%
34,521 $4.29 Million
Q1 2021

May 12, 2021

BUY
$127.04 - $179.1 $9.65 Million - $13.6 Million
75,922 Added 788.96%
85,545 $13.1 Million
Q4 2020

Feb 10, 2021

SELL
$99.96 - $135.93 $2.57 Million - $3.49 Million
-25,694 Reduced 72.75%
9,623 $1.24 Million
Q3 2020

Nov 12, 2020

SELL
$80.32 - $111.8 $1.36 Million - $1.9 Million
-16,981 Reduced 32.47%
35,317 $3.95 Million
Q2 2020

Aug 13, 2020

BUY
$60.49 - $97.5 $1.06 Million - $1.7 Million
17,455 Added 50.1%
52,298 $4.24 Million
Q1 2020

May 13, 2020

BUY
$59.04 - $88.81 $522,563 - $786,057
8,851 Added 34.05%
34,843 $2.43 Million
Q4 2019

Feb 10, 2020

BUY
$59.49 - $82.78 $573,662 - $798,247
9,643 Added 58.98%
25,992 $2.03 Million
Q3 2019

Nov 12, 2019

BUY
$62.59 - $110.3 $946,673 - $1.67 Million
15,125 Added 1235.7%
16,349 $1.04 Million
Q2 2019

Aug 09, 2019

BUY
$63.94 - $91.11 $78,262 - $111,518
1,224 New
1,224 $106,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $4.55B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.